Novo Nordisk Stock Drops 15% After CagriSema Fails to Beat Zepbound in Head-to-Head Trial — What This Means for GLP-1 Patients

Eli Lilly's lead in the GLP-1 obesity market just got bigger. Novo Nordisk's highly anticipated CagriSema — the combination of cagrilintide and semaglutide — failed to outperform Zepbound (tirzepatide) in the Phase III REDEFINE 4 head-to-head trial, sending Novo Nordisk's stock down 15% in its biggest single-day decline in company history.

The Numbers: CagriSema vs. Zepbound

The open-label REDEFINE 4 trial directly compared CagriSema (2.4/2.4 mg) to tirzepatide in adults with obesity over 84 weeks:

• CagriSema: 20.2% mean weight loss
• Zepbound: 23.6% mean weight loss
• Difference: 3.4 percentage points in favor of Zepbound (P<0.001)

CagriSema did achieve 22.7% weight loss in the REDEFINE 1 trial (adults with overweight/obesity and a weight-related condition, no diabetes), but the head-to-head comparison against Lilly's drug clearly favored tirzepatide.

What This Means for Novo Nordisk

The 15% stock drop wipes out roughly $40 billion in market capitalization — a stark reminder of how high investor expectations are for the GLP-1 space. Novo Nordisk now faces questions about whether its pipeline can close the gap with Lilly, which has:

• Zepbound (tirzepatide) — 23.6% weight loss in trial
• Retatrutide (triple agonist) — up to ~29% weight loss in Phase III
• Oral semaglutide (Wegovy pill) — newly approved

CagriSema was supposed to be Novo's answer to Lilly's dominance. Instead, the data suggests patients seeking maximum weight loss may be better served by tirzepatide-based therapies.

What This Means for Patients

If you're currently choosing between GLP-1 treatments or considering starting therapy, the head-to-head data is now clear:

• Tirzepatide (Zepbound/Mounjaro) currently delivers the greatest weight loss of any approved GLP-1/GIP therapy
• Semaglutide (Wegovy/Ozempic) remains highly effective at ~13-14% weight loss
• CagriSema fell between the two but didn't exceed either

"The trial results are disappointing for Novo but informative for patients," said Dr. Nadine Wulf, endocrinologist at Georgetown University Medical Center. "We now have robust comparative data showing tirzepatide produces the strongest weight loss results. For patients prioritizing efficacy, Zepbound remains the leader."

The Bigger Picture

Despite the setback, Novo Nordisk remains the world's most valuable company and continues to scale Wegovy and Ozempic production. The oral semaglutide approval earlier this month gives Novo a differentiation angle (no injections needed). However, the REDEFINE 4 results confirm what many in the medical community suspected: Lilly's dual-GIP/GLP-1 approach has a meaningful efficacy edge over Novo's GLP-1-only strategy.

For patients, the GLP-1 market is entering a new phase — one where comparative effectiveness data helps inform choices rather than just availability. If cost and access were the primary barriers, the recent TrumpRx pricing ($350/month for uninsured) and Medicare deals ($50/month for Zepbound) address affordability. Now efficacy data gives patients and physicians more confidence in choosing the right therapy.

The obesity drug race isn't over — but Lilly has extended its lead.